New drug cocktail aims to tame deadly transplant complication
NCT ID NCT07509749
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug ruxolitinib to standard steroid treatment can better control severe acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. The study will enroll 54 people who develop severe GVHD within 100 days of their transplant. The main goal is to see if more patients achieve a complete or partial response by day 28 of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib and methylprednisolone
What this could lead to
If successful, this could offer a more effective first-line treatment for severe acute GVHD, improving response rates and survival after stem cell transplants.
What could go wrong
This is a small phase 2 trial with only 54 participants, so results may not apply broadly. The combination therapy also carries risks like infection and side effects from steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEM CELL TRANSPLANT COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, the Fifth Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••